Drug Pricing News 20 December 2025

Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

NEW YORK, December 29, 2025, 22:14 ET Novo Nordisk said it is lowering prices of its top-selling obesity drug Wegovy in China, after local outlet Yicai reported that list prices for the two highest doses were cut by 48% in

30 December 2025

Merck (MRK) Stock Update: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Analyst Targets as Wall Street Heads Into New Year Week

As of 10:40 p.m. ET in New York on Friday, Dec. 26, 2025, U.S. markets have wrapped up the post-Christmas session and are heading into a weekend — leaving investors to digest a fresh cluster of headline catalysts around Merck

27 December 2025

Drug Pricing · FDA News · Pharmaceuticals · Stock Market · Wall Street Analysis

Merck & Co. (MRK) Enters 2026 in the Spotlight: BMO Upgrade to $130, FDA Fast-Track Vouchers and TrumpRx Pricing Deal Reframe the Post-Keytruda Story

December 25, 2025 — Even with U.S. markets closed for Christmas Day, Merck & Co., Inc. (NYSE: MRK) is ending 2025 as one of the most-watched large-cap pharma names on Wall Street. The stock closed at $106.45 on Wednesday, Dec.

25 December 2025

Biotech Industry · Drug Pricing · FDA Approvals · Pharmaceuticals

Bristol-Myers Squibb (BMY) Stock News Today: Supreme Court Bid, Drug-Pricing Deals, Dividend Boost, and 2026 Forecasts (Dec. 23, 2025)

Bristol-Myers Squibb Company (NYSE: BMY) stock is back in the spotlight on Tuesday, December 23, 2025, as investors weigh a fast-moving U.S. drug-pricing landscape, fresh legal headlines tied to Medicare negotiations, and new analyst commentary on competitive pressure in a

23 December 2025

Dividend Updates · Drug Pricing · Financial Forecasts · Pharmaceutical Industry · Stock Market News

AbbVie Stock (ABBV) Before the Market Opens on Dec. 22, 2025: Drug-Pricing Talks, Dividend Signals, and the Next Catalysts

AbbVie Inc. (NYSE: ABBV) heads into the Monday, December 22, 2025 U.S. market open with a familiar bull case—Skyrizi and Rinvoq continuing to replace lost Humira revenue—and a less familiar overhang: Washington’s accelerating push to reframe U.S. drug pricing through

22 December 2025

Dividend Investing · Drug Pricing · Financial News · Pharmaceuticals · Stock Market

AbbVie Stock Week Ahead (Dec. 22–26, 2025): ABBV Holds Near $227 as Drug-Pricing Headlines Collide With Fresh Analyst Upgrades

As of Sunday, December 21, 2025, AbbVie Inc. (NYSE: ABBV) heads into a holiday-shortened trading week with shares hovering near the mid-$220s, after a high-volume rebound into Friday’s close. The setup for the week ahead is defined by two competing

21 December 2025

Drug Pricing · Financial News · Investment Analysis · Pharmaceuticals · Stock Market

Healthcare Stocks Outlook (Dec. 21, 2025): Drug-Price Deals, ACA Premium Shock, and 2026 Catalysts Investors Are Watching

Sunday, December 21, 2025 — With U.S. markets heading into a holiday-shortened final trading stretch, healthcare stocks are back in focus as investors weigh a year-end “Santa rally” against a fast-moving policy backdrop that is unusually direct for the sector:

21 December 2025

Drug Pricing · Healthcare Stocks · Investment Strategies · Market Outlook

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Christmas week is usually about thin liquidity and shorter trading hours, not blockbuster headlines. But pharma and biotech stocks head into the final full week of the year with a rare mix of policy shockwaves, deal-making, and FDA-driven volatility—all clustered

21 December 2025

Drug Pricing · FDA Updates · Mergers & Acquisitions · Weekly Outlook

Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching

Dec. 21, 2025 — Pfizer Inc. (NYSE: PFE) ends the week in the spotlight after management laid out a 2026 outlook that undershot some Wall Street expectations, while a string of pipeline updates, partnerships, and policy headlines reshaped the near-term

21 December 2025

Drug Pricing · Investment Strategies · Market Analysis · Pharmaceutical Industry · Stock Market

Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025)

Updated: December 20, 2025 Gilead Sciences, Inc. (NASDAQ: GILD) heads into the weekend with fresh policy headlines, a high-profile pricing agreement tied to the Trump administration’s TrumpRx initiative, and renewed attention on the company’s next-generation HIV portfolio. The combination has

20 December 2025

Drug Pricing · Investment Analysis · Pharmaceutical Industry · Stock Market

AbbVie Stock (ABBV) News Today: Drug-Pricing Deal Watch, Skyrizi/Rinvoq Momentum, and Fresh Wall Street Forecasts (Dec. 20, 2025)

December 20, 2025 — AbbVie Inc. (NYSE: ABBV) is closing out the week in the spotlight as U.S. drug-pricing policy headlines collide with a still-strong “post-Humira” growth narrative built around Skyrizi and Rinvoq. The stock finished the last regular session

20 December 2025

Drug Pricing · Investment Analysis · Pharma Industry · Stock Market · Wall Street

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

As of December 20, 2025, healthcare stocks are heading into year-end with a rare mix of policy clarity and policy risk—often at the same time. In the past 48 hours, the sector has been hit by major U.S. drug-pricing announcements,

20 December 2025

Biotech · Drug Pricing · Healthcare · Market Outlook · Stock Market

Drug Pricing News 20 December 2025 - 30 December 2025